Quantum transition in the high frequency artificial respiration (HFOV): Introduction on the market „of the vision a® “
HFOV: “Vision alpha” of Novalung
(openPR) - clear treatment advantages for patient, physician and care
The artificially respirating enterprise Novalung extended its Produktportfolio for therapies of the protektiven artificial respiration in the spring 2007 by a high frequency respirator (HFOV).
The vision a® is a respirator, which world-wide HFOV and conventional artificially respirating procedures in equipment unite for the first time. With a small button easy changing between different artificially respirating procedures (HFOV, spontaneous respiration, ventilation) is possible. Thus fast guarantee an optimum therapy can react to changes in the patient and.
The microprocessor-controlled vision a® captivates besides by highest reliability and its quiet function mode - an advantage not only for the patient, but also for physician and care. Numerous individually adjustable alarm functions, the use of flexible artificially respirating hoses as well as a Exspirationsfilter, which provide for sterility in the treatment room, are further advantages user-friendly.
Therapy protektive artificial respiration
With the vision a® a sufficient artificial respiration is ensured also with similar Tidalvolumen as the anatomical Totraum. The vision a® made possible thus an extremely lung-careful artificial respiration and represents perfect an addition of the therapy with the artificial lung, „iLA to the Membranventilator™ “- one of the core products Novalungs, which breathes outside of the body.
While the strength iLA of the Membranventilators™ is the complete elimination of carbon dioxide (ventilation), the strength of the vision lies a® in the optimal Oxygenierung (artificial respiration) of the patient. The combination of both devices makes thus application possible protektive artificially respirating strategy. The lung of the patient receives time to heal.
Invitation for the presentation of the vision a®
On that 17. Symposium intensive medicine and intensive care of 14. until 16 February 2007 in fair and Congress Centrum Bremen is for the first time publicly presented the vision a®. We invite you cordially to make itself at our conditions A1 a picture. The permission of the vision a® is expected in March 2007.
Background informations
Artificial respiration
Where is the medical need for a lung support It happens due to a heavy pneumonia or by a strong injury of the thorax: The lung malfunctioned and only an artificial respiration can save the life of the patient.
The mechanical artificial respiration is however a zweischneidiges sword. The breathing air is normally sucked with negative pressure into the human lung, while the respirator air presses into the respiratory system. But the positive pressure can damage the breath organ additionally: The alveoli will stretched, the gas exchange worsens, the artificially respirating pressure must far be increased - a vicious circle. ” By our products, which breathe outside of the body, the artificial respiration can be reduced or avoided and thus a further damage of the lung be prevented “, explains George Matheis, managing director of the Novalung GmbH. The lung receives time to heal.
Franziska Pound
Product manager
franziska.pfund@novalung.com
Novalung GmbH
Lotzenäcker 3
D-72379 Hechingen
Tel.: +49 7471 984 88 0
Fax: +49 7471 984 88 15
www.novalung.com
Novalung GmbH
The Novalung GmbH began 2002 as world-wide first a company with the marketing of an artificial lung, iLA the Membranventilator™, which is supplied in natural way by the human heart with blood. Meanwhile the procedure was established. „Larva in Germany “applies by hundred percent to Novalung: The complete creation of value chain, of research and development over production up to the marketing is settled in the Hechingen of Baden-Wuerttemberg.
Dieser Artikel wurde veröffentlicht auf
OpenPR - http://openpr.de/news/119521/Quantensprung-in-der-Hochfrequenzbeatmung-HFOV-Markteinfuehrung-der-Vision.html